Exelixis Stock Price. Everything You Need To Know About The Exelixis Stock!
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,223 full-time employees. The company went IPO on 2000-04-11. The firm is engaged in developing medicines and combination regimens at the forefront of cancer care. The company has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Exelixis Stock Price. Everything You Need To Know About The Exelixis Stock! performance
- Employees 1223
- Company HQ Alameda
- Website https://www.exelixis.com/
- EXEL Asset Type Common Stock
- EXEL Market Capitalization 7B
- Earnings Per Share 0.65
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth -0.986
Exelixis is a biotechnology company that specializes in the development and commercialization of innovative therapies for the treatment of cancer. With its cutting-edge research and a strong presence in the pharmaceutical industry, Exelixis offers an exciting investment opportunity for retail investors from Malaysia, Thailand, Indonesia, and Vietnam. To invest in Exelixis from these countries, you can utilize the services of Zorion, an investment platform that provides access to real US stocks and pre-IPO companies like Exelixis. Zorion offers investment insights and recommendations to help you make informed decisions about your investment, ensuring that you have all the necessary information at your fingertips. Additionally, Zorion provides resources and educational materials to further enhance your investment knowledge, helping you navigate the complex world of biotech investing. Investing in Exelixis allows you to be a part of the company’s mission to improve the lives of cancer patients through groundbreaking therapies. With its proven track record and potential for growth, Exelixis presents a compelling investment opportunity for retail investors in Malaysia, Thailand, Indonesia, and Vietnam. Start your investment journey with Zorion and seize the chance to support a company at the forefront of medical advancements while potentially reaping the benefits of your investment.
